Cargando…

Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease

Background: Alzheimer’s disease (AD) is a neurodegenerative disease that remains uncured. Its pathogenesis is characterized by the formation of β-amyloid (Aβ) plaques. The use of antigen-specific regulatory T cells (Tregs) through adoptive transfer has shown promise for the treatment of many inflamm...

Descripción completa

Detalles Bibliográficos
Autores principales: Saetzler, Valerie, Riet, Tobias, Schienke, Andrea, Henschel, Pierre, Freitag, Kiara, Haake, Alexander, Heppner, Frank L., Buitrago-Molina, Laura Elisa, Noyan, Fatih, Jaeckel, Elmar, Hardtke-Wolenski, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453937/
https://www.ncbi.nlm.nih.gov/pubmed/37626926
http://dx.doi.org/10.3390/cells12162115
_version_ 1785096066674196480
author Saetzler, Valerie
Riet, Tobias
Schienke, Andrea
Henschel, Pierre
Freitag, Kiara
Haake, Alexander
Heppner, Frank L.
Buitrago-Molina, Laura Elisa
Noyan, Fatih
Jaeckel, Elmar
Hardtke-Wolenski, Matthias
author_facet Saetzler, Valerie
Riet, Tobias
Schienke, Andrea
Henschel, Pierre
Freitag, Kiara
Haake, Alexander
Heppner, Frank L.
Buitrago-Molina, Laura Elisa
Noyan, Fatih
Jaeckel, Elmar
Hardtke-Wolenski, Matthias
author_sort Saetzler, Valerie
collection PubMed
description Background: Alzheimer’s disease (AD) is a neurodegenerative disease that remains uncured. Its pathogenesis is characterized by the formation of β-amyloid (Aβ) plaques. The use of antigen-specific regulatory T cells (Tregs) through adoptive transfer has shown promise for the treatment of many inflammatory diseases, although the effectiveness of polyspecific Tregs is limited. Obtaining a sufficient number of antigen-specific Tregs from patients remains challenging. Aims and Methods: To address this problem, we used an antibody-like single-chain variable fragment from a phage library and subsequently generated a chimeric antigen receptor (CAR) targeting β-amyloid. Results: The β-amyloid-specific CARs obtained were stimulated by both recombinant and membrane-bound Aβ isolated from the murine brain. The generated CAR-Tregs showed a normal Treg phenotype, were antigen-specific activatable, and had suppressive capacity. Conclusion: This study highlights the potential of CAR technology to generate antigen-specific Tregs and presents novel approaches for developing functional CARs.
format Online
Article
Text
id pubmed-10453937
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104539372023-08-26 Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease Saetzler, Valerie Riet, Tobias Schienke, Andrea Henschel, Pierre Freitag, Kiara Haake, Alexander Heppner, Frank L. Buitrago-Molina, Laura Elisa Noyan, Fatih Jaeckel, Elmar Hardtke-Wolenski, Matthias Cells Article Background: Alzheimer’s disease (AD) is a neurodegenerative disease that remains uncured. Its pathogenesis is characterized by the formation of β-amyloid (Aβ) plaques. The use of antigen-specific regulatory T cells (Tregs) through adoptive transfer has shown promise for the treatment of many inflammatory diseases, although the effectiveness of polyspecific Tregs is limited. Obtaining a sufficient number of antigen-specific Tregs from patients remains challenging. Aims and Methods: To address this problem, we used an antibody-like single-chain variable fragment from a phage library and subsequently generated a chimeric antigen receptor (CAR) targeting β-amyloid. Results: The β-amyloid-specific CARs obtained were stimulated by both recombinant and membrane-bound Aβ isolated from the murine brain. The generated CAR-Tregs showed a normal Treg phenotype, were antigen-specific activatable, and had suppressive capacity. Conclusion: This study highlights the potential of CAR technology to generate antigen-specific Tregs and presents novel approaches for developing functional CARs. MDPI 2023-08-21 /pmc/articles/PMC10453937/ /pubmed/37626926 http://dx.doi.org/10.3390/cells12162115 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Saetzler, Valerie
Riet, Tobias
Schienke, Andrea
Henschel, Pierre
Freitag, Kiara
Haake, Alexander
Heppner, Frank L.
Buitrago-Molina, Laura Elisa
Noyan, Fatih
Jaeckel, Elmar
Hardtke-Wolenski, Matthias
Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease
title Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease
title_full Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease
title_fullStr Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease
title_full_unstemmed Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease
title_short Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease
title_sort development of beta-amyloid-specific car-tregs for the treatment of alzheimer’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453937/
https://www.ncbi.nlm.nih.gov/pubmed/37626926
http://dx.doi.org/10.3390/cells12162115
work_keys_str_mv AT saetzlervalerie developmentofbetaamyloidspecificcartregsforthetreatmentofalzheimersdisease
AT riettobias developmentofbetaamyloidspecificcartregsforthetreatmentofalzheimersdisease
AT schienkeandrea developmentofbetaamyloidspecificcartregsforthetreatmentofalzheimersdisease
AT henschelpierre developmentofbetaamyloidspecificcartregsforthetreatmentofalzheimersdisease
AT freitagkiara developmentofbetaamyloidspecificcartregsforthetreatmentofalzheimersdisease
AT haakealexander developmentofbetaamyloidspecificcartregsforthetreatmentofalzheimersdisease
AT heppnerfrankl developmentofbetaamyloidspecificcartregsforthetreatmentofalzheimersdisease
AT buitragomolinalauraelisa developmentofbetaamyloidspecificcartregsforthetreatmentofalzheimersdisease
AT noyanfatih developmentofbetaamyloidspecificcartregsforthetreatmentofalzheimersdisease
AT jaeckelelmar developmentofbetaamyloidspecificcartregsforthetreatmentofalzheimersdisease
AT hardtkewolenskimatthias developmentofbetaamyloidspecificcartregsforthetreatmentofalzheimersdisease